Almac Group Completes £5million Research & Development Centre
February 23, 2021
Significant expansion of biocatalysis, flow chemistry, and peptide capacity
Craigavon, Northern Ireland – 23 February 2021 – Almac Sciences, a member of the Almac Group, has completed a £5 million investment in a new two-storey centre for biocatalysis, flow chemistry technologies and peptide research and development.
Almac Sciences has grown rapidly over the last 5 years with significant investments in its non-GMP and GMP manufacturing plants to support increased client manufacturing demands. Adding to this growth, the first phase of expansion for technology development has been completed with the opening of a new facility housing additional R&D scientists to develop new technology and projects for Almac’s established biocatalysis, flow chemistry and peptides businesses. Additional capacity has also been created to enable further growth of its chemical development offering.
The 2,000m2, two-storey dedicated technology centre is located at the Group’s global headquarter campus and consists of 32 fume hoods, an engineering workshop for tooling and has capacity to accommodate up to 100 employees. Active recruitment for 20 additional staff members is underway and with a significant number of projects already commenced.
The completion of this new facility further showcases Almac’s dedication to innovation and investment in technology as it continues to engineer its technology platforms for the pharmaceutical, biotechnology, life sciences and fine chemicals sectors and comes just months after Almac announced its multi-million pound investment to further develop a program to establish IN Silico Informed metaGenomic Harvesting Technology (INSIGHT) continuing its commitment to develop flow processes.
Professor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Arran Chemical Company commented: “The investment in this new, state-of-the-art facility has been critical to support the rapid expansion of our innovative technology offering across different disciplines. As our technology evolves, we are experiencing an ever-increasing pipeline of projects taking advantage of our integrated offering from development through to manufacture. It is an exciting time to be at Almac as our technology success breeds success. We look forward to driving innovation for our clients in this new centre.”
The next phase of development is currently underway with further announcements expected in the coming months.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.